<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Trial id="186411"><TitleDisplay>A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk</TitleDisplay><TitleOfficial>A Nested Case-Controlled Study Evaluating the Utility of Placental Protein 13 (PP13) Invitro Diagnostic Kit as a Diagnostic Aiding Tool in Assessment of the Risk for Developing Pre-eclampsia Necessitating Delivery Before 37 Weeks (Early-preeclampsia) Based on First Trimester Blood Testing of Pregnant Women With Low and Unknown Risk</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00572793</Identifier><Identifier type="Organisational Study">11063</Identifier></Identifiers><Indications/><BiomarkerNames><BiomarkerName id="27249" role="Disease marker" type="Genomic">Placental protein 13-like</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1007278" type="Company"><TargetEntity id="4296521247" type="organizationId">Diagnostic Technologies Ltd</TargetEntity></SourceEntity><SourceEntity id="27708" type="Company"><TargetEntity id="5035554581" type="organizationId">University of Kansas Medical Center</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="27708">University of Kansas Medical Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1007278">Diagnostic Technologies Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>431</PatientCountEnrollment><DateStart>2007-11-30T00:00:00Z</DateStart><DateEnd type="actual">2014-07-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-14T11:32:07Z</DateChangeLast><DateAdded>2014-05-13T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University of Kansas Medical Center; Kansas City; Kansas; 66160; United States</Affiliation><Email>mclark4@kumc.edu</Email><Name>Margee Clark</Name><Phone>(913) 588-6287</Phone></Contact><Contact type="Public contact"><Affiliation>University of Kansas Medical Center; Kansas City; Kansas; 66160; United States</Affiliation><Email>lsamuelson@kumc.edu</Email><Name>Linda Samuelson</Name><Phone>913-588-6287</Phone></Contact><Contact type="Public contact"><Affiliation>University of Kansas Medical Center; Kansas City; Kansas; 66160; United States</Affiliation><Email>dsutton@kumc.edu</Email><Name>Dorinda Sutton</Name><Phone>(913) 588-6287</Phone></Contact><Contact type="Public contact"><Affiliation>University of Kansas Medical Center; Kansas City; Kansas; 66160; United States</Affiliation><Name>Carl Weiner</Name></Contact><Contact type="Scientific contact"><Affiliation>University of Kansas Medical Center</Affiliation><Name>Carl Weiner, MD, MBA</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy, pregnant females&lt;/li&gt;&lt;li&gt;Singleton fetus at 7 0/7 to 13 6/7 weeks gestation&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Multifetal pregnancy&lt;/li&gt;&lt;li&gt;Mental retardation&lt;/li&gt;&lt;li&gt;Known fetal anomaly or demise&lt;/li&gt;&lt;li&gt;BMI&amp;gt; 35 kg/m2, serious medical condition&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pre-eclampsia necessitating delivery at gestational age &lt; 37 weeks including HELLP syndrome and eclampsia</Description><Timeframe>37 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Maternal and neonatal morbidity and mortality and very early pre-eclampsia necessitating delivery before 34 weeks</Description><Timeframe>34 weeks, at delivery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate whether it is possible to detect changes in the      concentration of placental protein 13 (PP13) in the blood of pregnant women who may go on to develop the      complication of pre-eclampsia later on in the pregnancy, and if these changes can be detected      early enough to allow early diagnosis and treatment for prevention of these complications      and reduce their damage. This study would test if the PP13 biomarker during the first      trimester of pregnancy has the ability to provide assessment of risk for the development of      pre-eclampsia that necessitates delivery before 37 weeks gestation or can predict      pre-eclampsia before 34 weeks gestation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;After obtaining informed consent maternal demographics, vital signs, height, weight, medical history, pregnancy dating, dipstick for urine protein, previous lab results, nuchal translucency results and uterine artery Doppler results (if done) will be obtained. Blood for PP13 will be obtained at 7 to 13 weeks and optionally at 21 to 23 weeks. Hospitalization and delivery information will be obtained via a chart review for evidence of preeclampsia&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Kansas Medical Center</Name><Address1>Kansas City</Address1><Address2>Kansas</Address2><Address3>66160</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pregnancy Induced Hypertension</Disease><PatientSegments><PatientSegment><PatientSegment id="11145">Subjects with Risk for Preeclampsia Development</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00572793</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pregnancy Induced Hypertension" id="24324"><Endpoint>Assessment of Preeclampsia/Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24325">Assessment of eclampsia</SubEndpoint><SubEndpoint disease="Pregnancy Induced Hypertension" id="24326">Assessment of HELLP syndrome</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pregnancy Induced Hypertension" id="24338"><Endpoint>Assessment of Maternal Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24344">Assessment of pre-term births/deliveries</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pregnancy Induced Hypertension" id="24324"><Endpoint>Assessment of Preeclampsia/Related Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pregnancy Induced Hypertension" id="24375"><Endpoint>Assessment of Labor and Delivery Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24377">Assessment of induction of delivery</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pregnancy Induced Hypertension" id="24412"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Pregnancy Induced Hypertension" id="24415">Assessment of maternal mortality</SubEndpoint><SubEndpoint disease="Pregnancy Induced Hypertension" id="24416">Assessment of neonatal and infant mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pregnancy Induced Hypertension" id="24418"><Endpoint>Assessment of Morbidity</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pregnancy Induced Hypertension" id="21159"><Criterion>Pregnancy Related Other Inclusions</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="21160">Pregnant women in general health</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="21175">Subjects with singleton pregnancy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pregnancy Induced Hypertension" id="18794"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18796">Subjects co-morbid with CNS/neuropsychiatric disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18849"><Criterion>Exclusion based on Pregnancy</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18852">Fetal disorders</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="18861">Subjects with multifetal gestation/pregnancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-07-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-04-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>65.06 Months</EnrollmentPeriod><EnrollmentRate>6.62 Patients/Month</EnrollmentRate><DateFirstReceived>2007-12-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-08-01T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial>